USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Péter Bacsur  ¹     Mária Matuz  ²     Tamás Resál  ²     Pal Miheller  ³     Tamás Szamosi  ⁴     Eszter Schäfer  ⁴     Patrícia Sarlós  ⁵     Ákos Iliás  ⁶     Kata Szántó  ⁶     Mariann Rutka  ⁶     Anita Balint  ⁶     Ágnes Milassin  ⁶     Anna Fabian  ⁶     Renáta Bor  ⁶     Szepes Zoltán  ⁶     Tamás Molnár  ⁶     Klaudia Farkas  ^6    
1 Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
² Faculty of Pharmacy, University of Szeged, Szeged, Hungary
³ Semmelweis University, Budapest, Hungary
⁴ Military Hospital - State Health Centre, Budapest, Hungary
⁵ University of Pécs, Pécs, Hungary
⁶ Faculty of Medicine, Semmelweis University, Budapest, Hungary

Session
Investigator studies in IBD I (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)